Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Repurposing Clofazimine As a Novel Drug for the Treatment of PI-Resistant Stem Cell-like Subclones in Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Suman Mazumder, PhD, Sabyasachi Sanyal, PhD, Brian G. Van Ness, PhD, Amit Kumar Mitra, PhD MSc, BSc

Blood (2019) 134 (Supplement_1): 4418.

https://doi.org/10.1182/blood-2019-131596

Published: 2019

Journal Articles

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Li Chen, PhD, Amit Kumar Mitra, PhD MSc, BSc

Blood (2019) 134 (Supplement_1): 5543.

https://doi.org/10.1182/blood-2019-131923

Published: 2019

Journal Articles

Secdrug: A Computational Method for Discovering Novel Secondary Drug Combinations Using Large-Scale Pharmacogenomics Databases

Li Chen, PhD, Ujjal Kumar Mukherjee, PhD, Emily Rankine, Brian G. Van Ness, PhD, Amit Kumar Mitra, PhD

Blood (2018) 132 (Supplement 1): 4473.

https://doi.org/10.1182/blood-2018-99-117653

Published: 2018

Journal Articles

Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data

Shehroz Aslam, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Rida Riaz, MBBS, Muhammad Jahanzeb Khalil, MD, Faisal Mahfooz, MD, Madeeha Shafqat, Anum Qureshi, Insija Ilyas Selene, MBBS, Syed Shabee Hassan, MD, Muhammad Junaid Tariq, MD, Muhammad Yasir, MD, Sharoon Samuel, MBBS, Maryam Sadiq, MBBS, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 1950.

https://doi.org/10.1182/blood-2018-99-111587

Published: 2018

Journal Articles

A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Parameswaran Hari, MBBS, MD, Mark A. Schroeder, MD, James R Berenson, Andrzej Jakubowiak, MD PhD, Jonathan L Kaufman, MD, Peter M. Voorhees, MD, Hisaki Fujii, Zhao Yang, Francesco Galimi, MDPhD, Kenneth H. Shain, MD PhD

Blood (2018) 132 (Supplement 1): 803.

https://doi.org/10.1182/blood-2018-99-112610

Published: 2018

Journal Articles

Defining the Most Effective Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Andrej Besse, Lenka Besse, Marianne Kraus, Juergen Bader, Gerjan de Bruin, Herman S Overkleeft, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 5388.

https://doi.org/10.1182/blood.V130.Suppl_1.5388.5388

Published: 2017

Journal Articles

Developmental Compound E61 Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma Cells By Targeting the Cellular Protein Folding Machinery

Reeder McNeil Robinson, PhD, Leticia Reyes, Ravyn M. Thompson, Yefim Manevich, Jesse McClure, Matthew Champion, PhD, James Chou, Nathan G. Dolloff, PhD

Blood (2016) 128 (22): 1139.

https://doi.org/10.1182/blood.V128.22.1139.1139

Published: 2016

Journal Articles

Rethinking Risk-Benefit Assessment for Phase I Multiple Myeloma Trials

Ehsan Malek, MD, Caner Saygin, MD, Rebecca Ye, Byung-gyu Kim, DVM, Fahrettin Covut, MD, Marcos De Lima, MD, James J. Driscoll, MD PhD

Blood (2016) 128 (22): 1146.

https://doi.org/10.1182/blood.V128.22.1146.1146

Published: 2016

Journal Articles

Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies

Irene M. Ghobrial, MD, Michael R. Savona, MD, Ravi Vij, David S. Siegel, Ashraf Badros, Jonathan L. Kaufman, MD, Noopur Raje, MD, Andrzej Jakubowiak, MD PhD, Mihaela Obreja, Jesus G. Berdeja, MD

Blood (2016) 128 (22): 2110.

https://doi.org/10.1182/blood.V128.22.2110.2110

Published: 2016

Journal Articles

Glutaminase Inhibitor CB-839 Enhances Proteasome Inhibitor Sensitivity in Multiple Myeloma Cells

Ravyn M. Thompson, Leticia Reyes, Brittany Smith, Nathan G. Dolloff, PhD

Blood (2016) 128 (22): 3294.

https://doi.org/10.1182/blood.V128.22.3294.3294

Published: 2016

Journal Articles

Proteasome Inhibitor-Adapted Myeloma Cells That Lack Proteasome Gene Mutations Resist Highly Efficient Proteasome Inhibition and Show Proteomic Alterations That Suggest Complex Metabolic Changes

Lenka Besse, PhD, Guillem Soriano, Nan Li, Andrej Besse, Marianne Kraus, Juergen Bader, Tobias Christian Silzle, MD, Nico Meeuwenoord, Hans den Dulk, Herman S Overkleeft, Bogdan Florea, Christoph Driessen, MD

Blood (2015) 126 (23): 1278.

https://doi.org/10.1182/blood.V126.23.1278.1278

Published: 2015

Journal Articles

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Andrew Spencer, Simon Harrison, MD, Francis Burrows, Paul Mainwaring, MD, Timothy Price, MD, Michael J Millward, MD, Peeter Padrik, MD, Craig Underhill, MD, Paul Cannell, MD, Steven D Reich, MD, Mohit Trikha, PhD

Blood (2015) 126 (23): 5375.

https://doi.org/10.1182/blood.V126.23.5375.5375

Published: 2015

Journal Articles

Effects of Oprozomib in Combination with Pomalidomide and/or Dexamethasone on Human Multiple Myeloma Tumors Growing in SCID Mice

Eric Sanchez, BA, Mingjie Li, BS, Abigail Gillespie, BS, Puja Mehta, BS, Suzie Vardanyan, BS, Gigi Garzio, George Tang, PhD, Cathy Wang, BS, Haiming Chen, MD PhD, James R Berenson@imbcr.org, MD

Blood (2015) 126 (23): 5349.

https://doi.org/10.1182/blood.V126.23.5349.5349

Published: 2015

Journal Articles

The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone

Ana Alicia López-Iglesias, Ana Belen Herrero, Laura San-Segundo, Susana Hernández-García, Lorena González-Méndez, Montserrat Martín-Sánchez, Esperanza M Algarín, Teresa Paino, Mercedes Garayoa, Thomas Mehrling, MD PhD, Norma C Gutierrez, Jesús F. San-Miguel, MD, Maria-Victoria Mateos, Enrique M. Ocio, MD PhD

Blood (2015) 126 (23): 5354.

https://doi.org/10.1182/blood.V126.23.5354.5354

Published: 2015

Journal Articles

Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

Jatin Shah, Ruben Niesvizky, MD, Edward Stadtmauer, Robert M. Rifkin, James Berenson, MD, Jesus G. Berdeja, MD, Jeff P. Sharman, MD, Roger Lyons, Zandra Klippel, MD, Hansen Wong, Yu-Lin Chang, Saad Usmani

Blood (2015) 126 (23): 378.

https://doi.org/10.1182/blood.V126.23.378.378

Published: 2015

Journal Articles

Targeting Redox Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma

Nathan G. Dolloff, PhD, Leticia Reyes, Brittany Smith, John Fairbanks Langenheim, PhD, Yefim Manevich

Blood (2015) 126 (23): 1819.

https://doi.org/10.1182/blood.V126.23.1819.1819

Published: 2015

Journal Articles

Bortezomib Attenuates Adhesion of B Cell Precursor Acute Lymphoblastic Lleukemia Cells to Bone Marrow Mesenchymal Stromal/Stem Cells Via Regulating SPARC Expression

Masaki Iwasa, MD, Yasuo Miura, MD PhD, Aya Fujishiro, MD, Sumie Fujii, MD, Noriko Sugino, MD, Satoshi Yoshioka, MD, PhD, Akihiro Tamura, MD, Atsushi Sato, MD, Asumi Yokota, PhD, Katsuyuki Kito, MD PhD, Akira Ando, MD PhD, Hideyo Hirai, MD PhD, Akifumi Takaori-Kondo, MD PhD, Tatsuo Ichinohe, MDPhD, Taira Maekawa, MD PhD

Blood (2015) 126 (23): 786.

https://doi.org/10.1182/blood.V126.23.786.786

Published: 2015

Journal Articles

Creation of a Gene Expression Signature-Based Prediction Model Specific to Proteasome Inhibitor Response in Multiple Myeloma

Amit Kumar Mitra, PhD, Ujjal Mukherjee, PhD, Taylor Harding, Snigdhansu Chatterjee, PhD, Brian G Van Ness, PhD

Blood (2015) 126 (23): 3053.

https://doi.org/10.1182/blood.V126.23.3053.3053

Published: 2015

Journal Articles

Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)

David S. Siegel, MD PhD, Jonathan L. Kaufman, MD, Noopur S. Raje, MD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Steven P. Treon, MD PhD, Jorge J. Castillo, MD, Linda L. Neuman, MD MBA, Ju RueyJiuan Lee, PhD, Irene Ghobrial, MD

Blood (2014) 124 (21): 1715.

https://doi.org/10.1182/blood.V124.21.1715.1715

Published: 2014

Journal Articles

Modeling Myeloma Treatment through Epigenetic Modification: Synergistic Combination of EZH2 and Histone Deacetylase Inhibitors

Taylor S Harding, B.A., Jessica Swanson, Brian Van Ness, PhD

Blood (2014) 124 (21): 5719.

https://doi.org/10.1182/blood.V124.21.5719.5719

Published: 2014

NARROW

Repurposing Clofazimine As a Novel Drug for the Treatment of PI-Resistant Stem Cell-like Subclones in Myeloma

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Secdrug: A Computational Method for Discovering Novel Secondary Drug Combinations Using Large-Scale Pharmacogenomics Databases

Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data

A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Defining the Most Effective Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Developmental Compound E61 Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma Cells By Targeting the Cellular Protein Folding Machinery

Rethinking Risk-Benefit Assessment for Phase I Multiple Myeloma Trials

Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies

Glutaminase Inhibitor CB-839 Enhances Proteasome Inhibitor Sensitivity in Multiple Myeloma Cells

Proteasome Inhibitor-Adapted Myeloma Cells That Lack Proteasome Gene Mutations Resist Highly Efficient Proteasome Inhibition and Show Proteomic Alterations That Suggest Complex Metabolic Changes

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Effects of Oprozomib in Combination with Pomalidomide and/or Dexamethasone on Human Multiple Myeloma Tumors Growing in SCID Mice

The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone

Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

Targeting Redox Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma

Bortezomib Attenuates Adhesion of B Cell Precursor Acute Lymphoblastic Lleukemia Cells to Bone Marrow Mesenchymal Stromal/Stem Cells Via Regulating SPARC Expression

Creation of a Gene Expression Signature-Based Prediction Model Specific to Proteasome Inhibitor Response in Multiple Myeloma

Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)

Modeling Myeloma Treatment through Epigenetic Modification: Synergistic Combination of EZH2 and Histone Deacetylase Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only